AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus target price of $2.50 for the company and are anticipating that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given AVEO Pharmaceuticals an industry rank of 123 out of 265 based on the ratings given to related companies.
Several analysts have recently commented on the company. FBR & Co reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Saturday, April 8th. Piper Jaffray Companies set a $2.00 price objective on AVEO Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, June 24th. Zacks Investment Research lowered AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 27th. Finally, ValuEngine upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/08/11/aveo-pharmaceuticals-inc-aveo-given-consensus-recommendation-of-strong-buy-by-analysts-updated-updated-updated.html.
Several hedge funds have recently modified their holdings of the stock. Paloma Partners Management Co acquired a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at approximately $184,000. UBS Oconnor LLC acquired a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at approximately $291,000. Sabby Management LLC purchased a new position in shares of AVEO Pharmaceuticals during the first quarter worth about $513,000. Renaissance Technologies LLC raised its position in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock worth $1,482,000 after buying an additional 148,500 shares during the period. Finally, Sphera Funds Management LTD. purchased a new position in shares of AVEO Pharmaceuticals during the first quarter worth about $1,711,000. Hedge funds and other institutional investors own 50.96% of the company’s stock.
AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 2.66 on Monday. The stock’s market cap is $293.56 million. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $3.19. The stock has a 50 day moving average price of $0.89 and a 200 day moving average price of $0.73.
AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. The business had revenue of $2.53 million for the quarter. On average, analysts predict that AVEO Pharmaceuticals will post ($0.44) EPS for the current fiscal year.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about AVEO Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AVEO Pharmaceuticals Inc. and related companies.